These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18536780)

  • 1. A continuous regimen of levonorgestrel/ethinyl estradiol for contraception and elimination of menstruation.
    Jensen JT
    Drugs Today (Barc); 2008 Mar; 44(3):183-95. PubMed ID: 18536780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.
    Anderson FD; Gibbons W; Portman D
    Contraception; 2006 Mar; 73(3):229-34. PubMed ID: 16472561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, randomized study of an extended cycle oral contraceptive.
    Anderson FD; Hait H
    Contraception; 2003 Aug; 68(2):89-96. PubMed ID: 12954519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial.
    Kwiecien M; Edelman A; Nichols MD; Jensen JT
    Contraception; 2003 Jan; 67(1):9-13. PubMed ID: 12521651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
    Darwish M; Bond M; Ricciotti N; Hsieh J; Fiedler-Kelly J; Grasela T
    Reprod Sci; 2014 Nov; 21(11):1401-10. PubMed ID: 24647707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms.
    Jensen JT; Archer DF
    Expert Opin Pharmacother; 2008 Feb; 9(2):319-27. PubMed ID: 18201154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers.
    Mueck AO; Seeger H; Petersen G; Schulte-Wintrop E; Wallwiener D
    Contraception; 2001 Dec; 64(6):357-62. PubMed ID: 11834234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year, multicenter study of a triphasic, low-dose, combination oral contraceptive.
    Woutersz TB; Korba VD
    Int J Fertil; 1988; 33(6):406-10. PubMed ID: 2906915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new ultra-low-dose combination oral contraceptive.
    Woutersz TB
    J Reprod Med; 1983 Jan; 28(1 Suppl):81-4. PubMed ID: 6403705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization.
    Hampton RM; Fisher AC; Pagano S; LaGuardia KD
    Fertil Steril; 2009 Aug; 92(2):434-40. PubMed ID: 18930189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
    Archer DF; Jensen JT; Johnson JV; Borisute H; Grubb GS; Constantine GD
    Contraception; 2006 Dec; 74(6):439-45. PubMed ID: 17157099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended- and continuous-cycle oral contraceptives.
    Shrader SP; Dickerson LM
    Pharmacotherapy; 2008 Aug; 28(8):1033-40. PubMed ID: 18657019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous oral contraception. Strategies for managing breakthrough bleeding.
    Freeman SB
    Adv Nurse Pract; 2008 Aug; 16(8):36-8. PubMed ID: 19181174
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel.
    Larsson-Cohn U; Wallentin L; Zador G
    Horm Metab Res; 1979 Jul; 11(7):437-40. PubMed ID: 225252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in hormonal contraception. A new micro-pll with especially low hormone effect].
    Gynakologe; 1994 Apr; 27(2 Suppl):1-12. PubMed ID: 9131064
    [No Abstract]   [Full Text] [Related]  

  • 17. Contraception with levonorgestrel, 0.15 mg, and ethinyl estradiol, 0.03 mg. Clinical studies in Latin America.
    Moggia AV
    J Reprod Med; 1983 Jan; 28(1 Suppl):77-80. PubMed ID: 6403704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
    Kaunitz AM; Portman DJ; Hait H; Reape KZ
    Contraception; 2009 May; 79(5):350-5. PubMed ID: 19341846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral contraception with a triphasic combination of gestodene and ethinyl estradiol: results of a multicenter clinical study.
    Skouby SO
    Int J Fertil; 1987; 32 Suppl():45-8. PubMed ID: 2906346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 150/30 formulation. Experience in the United Kingdom.
    Guillebaud J
    J Reprod Med; 1983 Jan; 28(1 Suppl):66-70. PubMed ID: 6403702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.